Overview
To evaluate whether probiotics PS23 can improve the symptoms of patients with long COVID-19 ; also to evaluate the effects on blood cortisol and inflammation-related indicators in patients.
Description
It is expected that a total of 120 subjects will be recruited within 3 years after IRB approval, divided into two groups of 60 subjects, respectively consuming PS23 heat-treated bacteria or placebo, and completing the 6-week period.
Eligibility
Inclusion Criteria:
- Aged above 20 years old and below 65 years old.
- Those who consciously have long COVID-19 symptoms or actively respond to website advertisements to express interest in participating in this clinical researcher.
- Those who received the confirmation SMS or the COVID-19 rapid test positive 4 weeks ago.
Exclusion Criteria:
- Have taken antibiotics within one month or are receiving antibiotic treatment.
- Have taken probiotic products have been used within two weeks (excluding yogurt, yogurt, Yakult and other related foods).
- Cancer or immunocompromised patients undergoing treatment.
- Those who are allergic to lactic acid bacteria products.
- Diagnosed with dementia before being diagnosed with COVID-19.
- Prior to or currently taking medication for acute or psychiatric illness prior to the diagnosis of COVID-19.
- The investigator judges that it is not suitable to participate in the researcher.
